These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 36003370)

  • 1. A Pan-Pneumovirus vaccine based on immunodominant epitopes of the fusion protein.
    Huang J; Miller RJ; Mousa JJ
    Front Immunol; 2022; 13():941865. PubMed ID: 36003370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge.
    Gilbert BE; Patel N; Lu H; Liu Y; Guebre-Xabier M; Piedra PA; Glenn G; Ellingsworth L; Smith G
    Vaccine; 2018 Dec; 36(52):8069-8078. PubMed ID: 30389195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Potent Neutralizing Site III-Specific Human Antibody Neutralizes Human Metapneumovirus
    Bar-Peled Y; Diaz D; Pena-Briseno A; Murray J; Huang J; Tripp RA; Mousa JJ
    J Virol; 2019 Oct; 93(19):. PubMed ID: 31292250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human antibody recognition of antigenic site IV on Pneumovirus fusion proteins.
    Mousa JJ; Binshtein E; Human S; Fong RH; Alvarado G; Doranz BJ; Moore ML; Ohi MD; Crowe JE
    PLoS Pathog; 2018 Feb; 14(2):e1006837. PubMed ID: 29470533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Chimeric Pneumovirus Fusion Protein Carrying Neutralizing Epitopes of Both MPV and RSV.
    Wen X; Pickens J; Mousa JJ; Leser GP; Lamb RA; Crowe JE; Jardetzky TS
    PLoS One; 2016; 11(5):e0155917. PubMed ID: 27224013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of Epitope-Specific Anti-Respiratory Syncytial Virus (Anti-RSV) Antibody Responses after Natural Infection and after Vaccination with Formalin-Inactivated RSV.
    Widjaja I; Wicht O; Luytjes W; Leenhouts K; Rottier PJM; van Kuppeveld FJM; Haijema BJ; de Haan CAM
    J Virol; 2016 Jul; 90(13):5965-5977. PubMed ID: 27099320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VLPs generated by the fusion of RSV-F or hMPV-F glycoprotein to HIV-Gag show improved immunogenicity and neutralizing response in mice.
    Trinité B; Durr E; Pons-Grífols A; O'Donnell G; Aguilar-Gurrieri C; Rodriguez S; Urrea V; Tarrés F; Mane J; Ortiz R; Rovirosa C; Carrillo J; Clotet B; Zhang L; Blanco J
    Vaccine; 2024 May; 42(15):3474-3485. PubMed ID: 38641492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle vaccine: Structure, antigenic profile, immunogenicity, and protection.
    Patel N; Massare MJ; Tian JH; Guebre-Xabier M; Lu H; Zhou H; Maynard E; Scott D; Ellingsworth L; Glenn G; Smith G
    Vaccine; 2019 Sep; 37(41):6112-6124. PubMed ID: 31416644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody Epitopes of Pneumovirus Fusion Proteins.
    Huang J; Diaz D; Mousa JJ
    Front Immunol; 2019; 10():2778. PubMed ID: 31849961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elicitation of pneumovirus-specific B cell responses by a prefusion-stabilized respiratory syncytial virus F subunit vaccine.
    Phung E; Chang LA; Mukhamedova M; Yang L; Nair D; Rush SA; Morabito KM; McLellan JS; Buchholz UJ; Mascola JR; Crank MC; Chen G; Graham BS; Ruckwardt TJ
    Sci Transl Med; 2022 Jun; 14(650):eabo5032. PubMed ID: 35731888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure, Immunogenicity, and Conformation-Dependent Receptor Binding of the Postfusion Human Metapneumovirus F Protein.
    Huang J; Chopra P; Liu L; Nagy T; Murray J; Tripp RA; Boons GJ; Mousa JJ
    J Virol; 2021 Aug; 95(18):e0059321. PubMed ID: 34160259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-Based Design and Antigenic Validation of Respiratory Syncytial Virus G Immunogens.
    Nuñez Castrejon AM; O'Rourke SM; Kauvar LM; DuBois RM
    J Virol; 2022 Apr; 96(7):e0220121. PubMed ID: 35266806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Profiling of hMPV F-specific antibodies isolated from human memory B cells.
    Xiao X; Fridman A; Zhang L; Pristatsky P; Durr E; Minnier M; Tang A; Cox KS; Wen Z; Moore R; Tian D; Galli JD; Cosmi S; Eddins MJ; Sullivan NL; Yan X; Bett AJ; Su HP; Vora KA; Chen Z; Zhang L
    Nat Commun; 2022 May; 13(1):2546. PubMed ID: 35538099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector.
    Liang B; Ngwuta JO; Herbert R; Swerczek J; Dorward DW; Amaro-Carambot E; Mackow N; Kabatova B; Lingemann M; Surman S; Yang L; Chen M; Moin SM; Kumar A; McLellan JS; Kwong PD; Graham BS; Schaap-Nutt A; Collins PL; Munir S
    J Virol; 2016 Nov; 90(21):10022-10038. PubMed ID: 27581977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of potent RSV neutralizing antibodies isolated from human memory B cells and identification of diverse RSV/hMPV cross-neutralizing epitopes.
    Xiao X; Tang A; Cox KS; Wen Z; Callahan C; Sullivan NL; Nahas DD; Cosmi S; Galli JD; Minnier M; Verma D; Babaoglu K; Su H; Bett AJ; Vora KA; Chen Z; Zhang L
    MAbs; 2019; 11(8):1415-1427. PubMed ID: 31402751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-neutralization of four paramyxoviruses by a human monoclonal antibody.
    Corti D; Bianchi S; Vanzetta F; Minola A; Perez L; Agatic G; Guarino B; Silacci C; Marcandalli J; Marsland BJ; Piralla A; Percivalle E; Sallusto F; Baldanti F; Lanzavecchia A
    Nature; 2013 Sep; 501(7467):439-43. PubMed ID: 23955151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural basis for respiratory syncytial virus and human metapneumovirus neutralization.
    Miller RJ; Mousa JJ
    Curr Opin Virol; 2023 Aug; 61():101337. PubMed ID: 37544710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein.
    Cimica V; Boigard H; Bhatia B; Fallon JT; Alimova A; Gottlieb P; Galarza JM
    Clin Vaccine Immunol; 2016 Jun; 23(6):451-9. PubMed ID: 27030590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved Prefusion Stability, Optimized Codon Usage, and Augmented Virion Packaging Enhance the Immunogenicity of Respiratory Syncytial Virus Fusion Protein in a Vectored-Vaccine Candidate.
    Liang B; Ngwuta JO; Surman S; Kabatova B; Liu X; Lingemann M; Liu X; Yang L; Herbert R; Swerczek J; Chen M; Moin SM; Kumar A; McLellan JS; Kwong PD; Graham BS; Collins PL; Munir S
    J Virol; 2017 Aug; 91(15):. PubMed ID: 28539444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent cross-neutralization of respiratory syncytial virus and human metapneumovirus through a structurally conserved antibody recognition mode.
    Wen X; Suryadevara N; Kose N; Liu J; Zhan X; Handal LS; Williamson LE; Trivette A; Carnahan RH; Jardetzky TS; Crowe JE
    Cell Host Microbe; 2023 Aug; 31(8):1288-1300.e6. PubMed ID: 37516111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.